SUMMARY ANSWER: Naringenin suppresses proliferation and increases apoptosis via depolarization of mitochondrial membrane potential and generation of reactive oxygen species (ROS) in human endometriosis cells.
Introduction
Endometriosis is one of the most frequently diagnosed benign gynecological diseases in which endometrial glands and stromal cells grow outside of the uterus, particularly on the ovaries, oviducts and peritoneal tissues causing pelvic pain and infertility of women of reproductive age (Yoshino et al., 2004) . Importantly, endometriosis is the cause of infertility in 35-50% of fertile women between 25 and 35 years of age (Vigano et al., 2004; Bulun, 2009) . The pathogenesis of endometriosis is not clear because the focus of studies has been on management of symptoms rather than causes and therapies to cure the disease. The major hypothesis associated with initiation of endometriosis is retrograde menstruation. This hypothesis is based on evidence that endometrial cells and tissue fragments moved through the oviducts with retrograde menstrual flux and attach to the ovaries and/or tissues in the peritoneal cavity (Giudice, 2010; Burney and Giudice, 2012) . In the presence of endometrial cells outside of the uterine lumen and pelvic contamination increase leading to a concentration of inflammatory cytokines related to circulating concentrations of estrogens (Yoshino et al., 2004; Bulun, 2009 ). The gold standard for management of endometriosis is surgery for removal of endometriotic tissues and, in extreme cases, removal of the uterus and ovaries, as well as therapies to reduce inflammation and pain (Eskenazi et al., 2001; Somigliana et al., 2010) . Treatment for endometriosis is classified into two groups; management of pain and management of infertility. For pain management, resection of lesions is mainly performed, but there are risks of complications and one of four patients suffer from recurrence of pain (Vercellini et al., 2009; De Cicco et al., 2011) . A GnRH agonist is considered most effective for management of pain as it results in a hypoestrogenic condition and it suppresses proliferation of endometrial cells (Johnson et al., 2013) . However, GnRH therapy has side effects including negative calcium balance and genital hypotrophy because of the hypoestrogenic condition and GnRH agonists are the most expensive compounds for treatment of endometriosis (Vercellini et al., 2008) . Infertility from endometriosis is caused by chorionic pelvic inflammation; therefore, IVF is recommended for patients who wish to become pregnant (de Ziegler et al., 2010) .
Naringenin belongs to the family of flavanones that include six categories of flavonoids; flavonols, flavones, flavanones, isoflavones, catechins and anthocyanidins. Naringenin is abundant in grapefruits and oranges (Kawaii et al., 1999) . Flavanones are well known for having anti-cancer, anti-mutagenic, anti-inflammatory and anti-oxidant activities and naringenin is a flavanone with significant anti-proliferative and anti-oxidant properties (Patel et al., 2014) . For example, naringenin is an effective inhibitor of proinflammatory cytokines and phosphorylation of transcription factors in macrophages (Bodet et al., 2008) . And naringenin is used in conjunction with L-arginine to reduce oxidative stress (Ahmed et al., 2014) . In addition, naringenin inhibits aromatase which converts testosterone to estradiol (Jeong et al., 1999) .
Consumption of soybeans and treatment with lignan are useful in management strategies to ameliorate symptoms of menopause and inhibit aromatase activity without significantly altering concentrations of estrogens in plasma of women (Hale et al., 2000; Celec et al., 2005) . Naringenin decreased the activity of human recombinant aromatase through a direct interaction with the enzyme in a cell free assay (Edmunds et al., 2005) . Naringenin also modifies estrogen receptor alpha signaling by interfering with activation of extracellular signalregulated kinases (ERK1/2) mitogen-activated protein kinase (MAPK) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling pathways (Galluzzo et al., 2008) . Therefore, the therapeutic use of naringenin may be a valuable therapeutic for treatment of patients with endometriosis.
In the present study, we investigated the anti-proliferative effects of naringenin on two endometriosis cell lines (VK2/E6E7 and End1/E6E7) at the cellular and molecular level. The specific objectives of this study were to: (i) determine effects of naringenin on viability of endometriosis cells; (ii) verify the apoptotic effects of naringenin on endometriosis cells; (iii) determine if reactive oxygen species (ROS) production and mitochondrial apoptotic pathways activated by naringenin lead to death of endometriosis cells; and (iv) identify cell signaling molecules responsible for effects of naringenin on proliferation and apoptosis of endometriosis cells. Results of this study provide the first evidence that naringenin has anti-proliferative effects on endometriosis cells that are mediated mainly via the MAPK and AKT (Protein kinase B) cell signaling pathways. Cell culture VK2/E6E7, vaginal mucosa derived epithelial endometriosis cells, and End1/E6E7, endocervix epithelial derived endometriotic cells, were purchased from the American Type Culture Collection (ATCC) and cultured in serum free medium (GIBCO, Waltham, MA, USA) with human recombinant epidermal growth factor (EGF; 0.1 ng/mL) and bovine pituitary extract (0.05 mg/mL) at 37°C in an incubator with an atmosphere of 5% CO 2 . For experiments, monolayer cultures of VK2/E6E7 and End1/ E6E7 cells were grown in culture medium to 70% confluence in 100-mm tissue culture dishes. Cells were treated with a different dose of naringenin with or without inhibitors of cell signaling pathways. Human endometrial cells were prepared from eutopic endometrial tissue from endometriosis patients as described previously (Tuckerman et al., 2000; Laird et al., 2011) . The patients ranged in age from 20 to 45 years, with a mean age of 35 years, and all were in the proliferative phase of the menstrual cycle. The tissue was cut into small pieces and placed in high glucose Dulbecco's modified Eagle medium (DMEM) (Cat No: SH30243.01, Hyclone, USA) with 2 mg/ml collagenase A (Cat No: 10 103 578 001, Roche Diagnostics GmbH) and incubated at 37°C under an atmosphere of 5% CO 2 for 1 h. Epithelial cells were separated from stromal cells by centrifugation at 100 g for 5 min. The pellet contained epithelial cells, mainly present as glands and this pellet was resuspended in 5 ml DMEM with 2 mg/ml collagenase A and incubated for another 1 h. For experiments, monolayer cultures of VK2/E6E7 and End1/E6E7 cells were grown in culture medium to 70% confluence in 100-mm tissue culture dishes at 37°C in an incubator with an atmosphere of 5% CO 2 .
Materials and Methods

Chemicals
Proliferation assay
Proliferation assays were conducted using a Cell Proliferation ELISA, BrdU kit (Cat No. 11 647 229 001, Roche, Indianapolis, IN, USA) according to the manufacturer's recommendations. Briefly, VK2/E6E7 and End1/E6E7 cells were seeded in a 96-well plate, and then treated with naringenin (0, 5, 10, 20, 50 and 100 μM) with or without inhibitors (20 μM LY294002, inhibitor of PI3K/AKT; 10 μM U0126, inhibitor of ERK1/2; 10 μM SP600125, inhibitor of JNK; and 20 μM SB203580, inhibitor of P38) in a final volume of 100 μL/well. After 48 h of incubation, 10 μM bromo-2′-deoxyuridine (BrdU) was added to the cell culture and the cells were incubated for an additional 2 h at 37°C. After labeling of cells with BrdU, the fixed cells were incubated with anti-BrdU-peroxidase (POD) working solution for 90 min. The anti-BrdU-POD binds to BrdU incorporated in newly synthesized cellular DNA and these immune complexes were detected by their reaction with the 3,3′,5,5′-tetramethylbenzidine (TMB) substrate.
The absorbance values of the reaction product were determined by measuring the absorbance at 370 and 492 nm using an ELISA reader.
Immunofluorescence microscopy
The effects of naringenin on the expression of proliferating cell nuclear antigen (PCNA) were determined using immunofluorescence microscopy. Cells were incubated with or without naringenin (100 μM) for 24 h, at 37°C in a CO 2 incubator and probed with mouse anti-human monoclonal PCNA (Cat No. sc-56, Santa Cruz Biotechnology) at a final dilution of 1:100 (2 μg/ml). They were then incubated with goat anti-mouse IgG Alexa 488 (Cat No. A-11 001, Invitrogen, Carlsbad, CA, USA) at a 1:200 dilution for 1 h at room temperature. Cells were then washed using 0.1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) and overlaid with 4′,6-diamidino-2-phenylindole (DAPI). For each primary antibody, images were captured using a LSM710 (Carl Zeiss) confocal microscope. The intensity staining was assessed using Metamorph Offline software (Molecular Devices, Sunnyvale, CA, USA)
TUNEL assay
The VK2/E6E7 and End1/E6E7 cells (3 × 10 4 cells per 300 μL) were seeded on confocal dishes (Cat No. 100 350, SPL Life Science, Republic of Korea) and then treated with naringenin at a final concentration of 100 μM for 48 h at 37°C in a CO 2 incubator. After incubation, the cells were air dried and fixed with 4% paraformaldehyde in PBS for 1 h at room temperature. The cells were rinsed with PBS briefly and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice. Then, the cells were subjected to TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining mixture using the In Situ Cell Death Detection kit, TMR red (Cat No: 12 156 792 910, Roche Diagnostics GmbH, Germany) for 1 h at 37°C in the dark. Cells were then washed with PBS and overlaid with DAPI (Cat No. D8417, Sigma-Aldrich, Inc). Fluorescence was assessed using a LSM710 (Carl Zeiss) confocal microscope fitted with a digital microscope AxioCam camera with Zen2009 software. The intensity of fluorescence was determined using Metamorph Offline software (Molecular Devices).
Annexin V and propidium iodide staining
Apoptosis of endometriosis cells induced by naringenin was analyzed using an FITC Annexin V apoptosis detection kit I (BD Biosciences, Franklin Lakes, NJ, USA). The cells (5 × 10 5 cells) were seeded on 6-well plates and treated with naringenin in a dose-dependent manner (0, 20, 50 and 100 μM) for 48 h at 37°C in a CO 2 incubator. Supernatants were removed from culture dishes and adherent cells detached with trypsin-EDTA. The cells were collected by centrifugation, washed with PBS, and resuspended using 1× binding buffer at 1 × 10 6 cells/ml. Then, 100 μL of the cell suspension (1 × 10 6 cells) was transferred to a 5 mL culture tube and incubated with 5 μL FITC Annexin V and 5 μL PI for 15 min at room temperature in the dark. Then, 400 μL of 1× binding buffer was added in a 5 mL culture tube. Fluorescence intensity was determined using FACS Calibur (BD Biosciences).
Mitochondrial membrane potential assay
Changes in mitochondrial membrane potential (MMP) were analyzed using a Mitochondria staining kit (Cat No: CS0390, Sigma-Aldrich). The endometriosis cells (5 × 10 5 cells) were seeded in 6-well plates and treated with naringenin in a dose-dependent manner (0, 20, 50 and 100 μM) for 48 h at 37°C in a CO 2 incubator. Valinomycin served as a positive control. Supernatants were removed from culture dishes and adherent cells detached with trypsin-EDTA. The cells were collected by centrifugation, resuspended in staining solution including 200× JC-1 and 1× staining buffer and incubated at 37°C in a CO 2 incubator for 20 min. The stained cells were collected by centrifugation and washed once with 1× JC-1 staining buffer. After washing, the cell suspension was centrifuged once more and then the cells were resuspended in 1 mL staining buffer. Fluorescence intensity was determined using FACSCalibur (BD Biosciences).
Western blot analysis
Concentrations of protein in whole-cell extracts were determined using the Bradford protein assay (Bio-Rad, Hercules, CA, USA) with BSA as the standard. Proteins were denatured, separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose. Blots were developed using enhanced chemiluminescence detection (SuperSignal West Pico, Pierce, Rockford, IL, USA) and quantified by measuring the intensity of light emitted from correctly sized bands under ultraviolet light using the ChemiDoc EQ system and Quantity One software (Bio-Rad, Hercules, CA, USA). Immunoreactive proteins were detected using goat anti-rabbit polyclonal antibodies against phosphorproteins and total-proteins at a 1:1000 dilution and 10% SDS/PAGE gel. Total proteins were used as a loading control to normalize results from detection of phosphorylated proteins by western blotting. All antibodies were from Cell Signaling Technology and Santa Cruz. Multiple exposures of each western blot were performed to ensure linearity of chemiluminescent signals.
Determination of cellular ROS
Intracellular ROS production was estimated using 2′-7′dichlorodihydrofluor-escein diacetate (H2DCF-DA) which is oxidized to fluorescent 2′,7′-dichlorofluorescein (DCF) in the presence of peroxides. Cells were detached with trypsin-EDTA, collected by centrifugation, and washed with PBS. The cells were treated with 10 μM H2DCF-DA for 30 min at 37°C. Then, the cells were washed twice with PBS and treated with naringenin in a dosedependent manner (0, 20, 50 and 100 μM) for 1 h at 37°C in a CO 2 incubator. Cells treated with hydrogen peroxide served as a positive control. The treated cells were washed again with PBS and then the fluorescent DCF intensity was analyzed using a FACSCalibur flow cytometer (BD Bioscience).
Lipid peroxidation
A Click-iT lipid peroxidation imaging kit (Invitrogen) was used according to the manufacturer's recommendation. Briefly, VK2/E6E7 and End1/E6E7 cells (3 × 10 4 cells per 300 μL) were seeded on confocal dishes and treated with 100 μM naringenin and 50 μM linoleamide alkyne (LAA) for 2 h at 37°C in a CO 2 incubator. After cell fixation (3.7% formaldehyde) and permeabilization (0.5% Triton X-100), the nucleophilic side chains of proteins modified by LAA oxidation were labeled by Alex Fluor 488 Azide for 30 min at room temperature. Fluorescence was detected using a LSM710 (Carl Zeiss) confocal microscope. The intensity of fluorescence was analyzed using Metamorph Offline software (Molecular Devices).
Ethical approval
Informed consent was obtained from each patient before surgery for the use of tissues for the present study. Approval for the use of endometrial tissue was granted by the Institutional Review Board of Korea University, Guro Hospital. [B] Immuno-reactive PCNA was abundant in non-treated endometriosis cells, but less (P < 0.001) in naringenin-treated VK2/E6E7 and End1/E6E7 cells. Nuclei of cells were counterstained with DAPI (blue). Scale bar represents 20 μm (the first horizontal panels) and 10 μm (the second horizontal panels). The intensity of fluorescence was detected using Metamorph software. The asterisks indicate a significant difference compared to vehicle treatment (***P < 0.001).
Statistical analysis
Data for proliferation and migration assays were subjected to analysis of variance (ANOVA) according to the general linear model (PROC-GLM) of the SAS program (SAS Institute, Cary, NC, USA) to determine if the significance of the effects of naringenin on proliferation and migration of VK2/E6E7 and End1/E6E7 cells. Differences with a probability value of P < 0.05 were considered statistically significant. Data are presented as mean ± SEM unless otherwise stated.
Results
Effect of naringenin on proliferation of human endometriosis cells
We conducted cell proliferation assays to determine dose-dependent effects of naringenin (0, 5, 10, 20, 50 and 100 μM) on proliferation of two endometriosis cell lines (Fig. 1A) . The proliferation of VK2/E6E7 and End1/E6E7 cells decreased with increasing doses of naringenin (P < 0.001). Proliferation of both cell lines decreased~50% in response to 100 μM naringenin. Based on those results, 100 μM naringenin was used in further experiments. Next, we compared expression of PCNA, a cell proliferation marker, between naringenin-treated and non-treated VK2/E6E7 and End1/E6E7 cells by immunofluorescence analyses (Fig. 1B) . PCNA was abundant in nuclei of cells in both vehicle-treated cell lines. However, it was significantly reduced in both cell lines after cells were treated with naringenin.
Effect of naringenin on apoptosis of human endometriosis cells
We assumed that the naringenin-induced decrease in proliferation of VK2/E6E7 and End1/E6E7 cell lines was due to cell cycle arrest and cell death. Thus, we investigated whether naringenin induced apoptosis of . Scale bar represents 20 μm (the first horizontal panels) and 10 μm (the second horizontal panels). The fluorescence intensity was detected using Metamorph software. The intensity of TUNEL Red in treated as compared to non-treatment cells. The asterisks indicate a significant difference compared to vehicle treatment (***P < 0.001, **P < 0.01 and *P < 0.05).
endometriosis cells in a dose-dependent manner (0, 20, 50 and 100 μM) using annexin V and propidium iodide (PI) dye. Naringenin increased apoptosis of VK2/E6E7 cells by~7-fold (P < 0.001) with 100 μM (Fig. 2A) . Naringenin also increased apoptosis of End1/E6E7 cells by 2-fold (P < 0.001) with 100 μM (Fig. 2B) . These results were confirmed in analyses for DNA fragmentation in endometriosis cells treated with naringenin (100 μM) based on the TUNEL reaction ( Fig. 2C and D) . DNA fragmentation in apoptotic cells was strongly detected in nuclei of both endometriosis cell lines. In addition, we evaluated the function of mitochondria in the apoptotic pathway using the mitochondrial membrane potential (MMP) assay and western blot analyses (Fig. 3) . The loss of MMP increased~1.5-fold (P < 0.001) in VK2/E6E7 cells in response to 100 μM naringenin (Fig. 3A) and 10-fold (P < 0.001) for End1/E6E7 cells (Fig. 3B ) compared to vehicle-treated control cells. As a positive control, we stained both endometriosis cells with valinomycin which is a chemical that induces disruption of mitochondrial gradients. We verified the mitochondria-dependent apoptosis pathway using western blot assays ( Fig. 3C and D) . The mitochondrial pro-apoptotic protein, Bax, increased in VK2/E6E7 cells in response to 100 μM naringenin, but Bak, another pro-apoptotic protein, was not affected by naringenin. However, both Bax and Bak proteins increased in response to naringenin in a dose-dependent manner in End1/E6E7 cells.
Naringenin induces ROS production and ER stress in endometriosis cells
Naringenin induced dose-dependent increases in cellular ROS production in both endometriosis cell lines ( Fig. 4A and B) . The production of ROS increased 3-fold (P < 0.001) in VK2/E6E7 cells and 2-fold (P < 0.001) in End1/E6E7 cells in response to 100 μM naringenin compared with vehicle-treated cells. As a positive control, we detected ROS production in both endometriosis cells in response to hydrogen peroxide. Furthermore, lipid peroxidation detected by LAA was increased (P < 0.001) in both VK2/E6E7 (Fig. 4C ) and End1/E6E7 cells treated with 100 μM naringenin (Fig. 4D) . Next, we determined naringenin-induced ER stressrelated proteins. The phosphorylation of eIF2α was slightly increased in both cells by naringenin treatment. Consistent with these results, inositol-requiring protein 1α (IRE1α), growth arrestand DNA damage-inducible gene 153 (GADD153) and glucoseregulated protein 78 (GRP78) proteins were notably increased VK2/E6E7 and End1/E6E7 in response to naringenin ( Fig. 4E and F). These results indicated that naringenin significantly increased generation of ROS and ER stress regulatory genes to induce cell death of endometriosis cells. The asterisks indicate a significant difference compared to vehicle treatment (***P < 0.001, **P < 0.01 and *P < 0.05).
Effects of naringenin on eutopic endometriosis cells
To confirm the cytotoxicity of the naringenin, we determined effects of naringenin on cell proliferation, apoptosis, ER stress and ROS production in eutopic endometriosis cells (Fig. 5) . Naringenin did not influence cell proliferation or apoptosis of the eutopic endometrial cells at the same doses used to treat VK2/E6E7 and End1/E6E7 cells ( Fig. 5A  and B) . Surprisingly, naringenin decreased ER stress regulatory proteins in the eutopic endometrial cells (Fig. 5C) . Expression of IRE1α, GADD153 and GRP78 proteins were significantly decreased in response to naringenin, but phosphorylation of eIF2α was not affected by naringenin (Fig. 5C ). Although ROS production increased in response to hydrogen peroxide (positive control), naringenin did not affect the generation of ROS in the eutopic endometrial cells (Fig. 5D ).
Naringenin affects PI3K/AKT and MAPK cell signaling pathways
We next determined changes in abundances of phosphorylated cell signaling proteins induced by naringenin using western blot analyses (Fig. 6 ). Naringenin did not exert dose-dependent effects on phosphorylation of ERK1/2 in VK2/E6E7 but decreased at 100 μM in End1/E6E7 cells (Fig. 6A) . However, the phosphorylation of P90RSK protein decreased in a dose-dependent manner in both cell lines (Fig. 6B) . The phosphorylation of P38 protein increased in a dose-dependent manner in both cell lines, whereas the abundance of phosphorylated JNK increased at 50 and 100 μM naringenin in VK2/E6E7 cells but, decreased at those doses of naringenin in End1/E6E7 cells ( Fig. 6C and  D) . Phosphorylated-AKT protein decreased in response to 100 μM naringenin compared to non-treated VK2/E6E7 endometriosis cells, while it increased in response to 20 μM naringenin and decreased in response to 100 μM naringenin in End1E6E7 cells (Fig. 6E) . Similarly, phosphorylation of P70S6K in response to naringenin was not dose-dependent in either VK2/E6E7 or End1/E6E7 cells (Fig. 6F) . The phosphorylation of the S6 protein was reduced by naringenin in a dose-dependent manner in both endometriosis cell lines (Fig. 6G) . We next confirmed the regulatory effects of naringenin in proliferation of the two endometriosis cell lines in the presence or absence of LY294002 (20 μM, PI3K inhibitor), U0126 (20 μM, ERK1/2 MAPK inhibitor), SB203580 (20 μM, P38 MAPK inhibitor) and SP600125 (20 μM, JNK MAPK inhibitor) on cell proliferation of VK2/E6E7 and End1/E6E7 cells as illustrated in Fig. 7 . A combination of naringenin with each of the pharmacological inhibitors indicated synergistic effects on reduction of proliferation of both endometriosis cell lines as compared to each inhibitor alone (P < 0.001). In addition, reduced cell proliferation of the endometriosis cell lines by naringenin was decreased most by the combination of naringenin and U0126 or SP600125 in VK2/E6E7 and End1/E6E7 cells. Thus, the decrease in proliferation of both endometriosis cell lines was most affected by inhibitors of MAPK and PI3K/AKT cell signaling pathways.
Inhibition of PI3K and MAPK signal transduction with naringenin indicated crosstalk in VK2/E6E7 and End1/E6E7 cells
To identify regulatory effects of the combination of naringenin with each inhibitor alone, we conducted western blot analyses (Fig. 8) . The naringenin-induced phosphorylation of ERK1/2 protein in the endometriosis cell lines was inhibited by U0126, but also reduced by SB203580 and SP600125 in VK2/E6E7 cells, with similar results for End1/E6E7 cells except that LY294002 increased phosphorylation of ERK1/2 (Fig. 8A) . However, the slight reduction in phosphorylation of P90RSK by naringenin was eliminated by combinations of naringenin with LY294002, U0126, SB203580 and SP600125 in VK2/E6E7 cells, but not End1/E6E7 cells (Fig. 8B) . The phosphorylation of P38 protein in response to naringenin-treated endometriosis cells was downregulated by U0126 and SB203580 (Fig. 8C) , but increased by SP600125 in VK2/E6E7, and LY294002 and SP600125 in End1/E6E7 cells. The phosphorylation of JNK in VK2/E6E7 naringenin cells was decreased by LY294002, U0126, SP600125 and SB203580; however, phosphorylation of JNK was increased by the combination of naringenin and SB203580 in End1/E6E7 cells. The phosphorylation of AKT in response to naringenin was decreased by LY294002, SP600125 and SB203580 in both endometriosis cell lines (Fig. 8E ). There was a decrease in phosphorylation of P70S6K in both the endometriosis cell lines treated with the combination of naringenin and LY294002 or U0126 (Fig. 8F) . Moreover, the S6 phosphorylation was completely blocked by a combination of naringenin with all of the inhibitors in VK2/E6E7 and End1/E6E7 cells (Fig. 8G) . These results indicate that naringenin regulated the PI3K and MAPK signaling molecules in endometriosis cells. Furthermore, the results showed that there are some synergic effects between naringenin and inhibitors to suppress, as well as, in a few cases, stimulate cell signaling molecules in endometriosis cells with respect to anti-proliferative effects endometriosis cells. [C] Changes in abundance of ER stress regulatory proteins eIF2α, IRE1α, GADD153 and GRP78 in response to naringenin were analyzed by western blotting.
[D] ROS production was estimated using flow cytometry based on the intensity of DCF fluorescence. As a positive control, cells were incubated in the presence of hydrogen peroxide instead of naringenin under the same culture conditions. The asterisks indicate a significant difference compared to vehicle treatment (***P < 0.001 and **P < 0.01). and 100 μM) were determined using western blot assays. Dose-dependent effects of naringenin on the phosphorylation of cell signaling molecules are presented for endometriosis cell lines relative to non-treated control cells. The graph was drawn after three independent experiments (***P < 0.001, **P < 0.005 and *P < 0.01). 
Discussion
In the present study, we demonstrated anti-proliferative and apoptotic effects of naringenin on two human endometriosis cell lines (VK2/ E6E7 and End1/E6E7). Our results indicate that naringenin induced apoptosis involves effects to decrease mitochondrial membrane potential and increase production of ROS in endometriosis cells. Those effects of naringenin are mediated through its activation of PI3K and MAPK cell signaling pathways in VK2/E6E7 and End1/E6E7 cells as illustrated in Fig. 9 . Endometriosis is a disease in which the endometrium grows outside of the uterus and is characterized by inflammation, chronic pelvic pain and infertility in some patients of reproductive age (Vercellini et al., 2011) . This disease increases medical costs~63% in the United States of America (Mirkin et al., 2007) and, in Canada, the social costs of endometriosis patients is $5200 per person annually (Levy et al., 2011) . Endometriosis affects 6-10% of women (Bulletti et al., 2010) mainly aged 15-49 years (Gylfason et al., 2010) . The main symptoms of endometriosis are pelvic pain but, individual pain areas and intensity are not always related to the lesions and severity and lesions react to hormonal stimulation during the menstruation cycle to induce stronger pain during the menstrual period (Ballard et al., 2010) . There is no proven pathogenesis of endometriosis and there is no fundamental treatment for endometriosis other than reducing pain with hormonal therapy and managing endometriosis-associated infertility (Vercellini et al., 2011) . Pharmacological therapy is controversial for treatments of endometriosis that focus on targeting the molecular factors in animal models (Soares et al., 2012) . For example, an anti-angiogenic agent, epigallocatechin gallate derived from green tea, significantly suppresses development of experimental human endometriosis cells in a mouse model ). In addition, trichostatin A and valproic acid reduce lesion size in a murine model of endometriosis, but clinical studies are limited to a few patients with endometriosis (Acien et al., 2003; Soares et al., 2012) . Even though GnRH agonists commonly decrease symptoms of endometriosis by regulating cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF-α) and nuclear factor-kappa B (NF-κB), specific intracellular signaling pathways or molecular targets are required for identification of pathogenesis of endometriosis. Therefore, it is important to find a novel therapeutic for treatment of endometriosis patients safely with knowledge of exact mechanisms of action.
Phytochemicals are emerging natural therapeutic molecules for treatment of a variety of cancers and chronic diseases because they have fewer side effects than synthetic compounds. However, there are few studies of the action of phytochemicals in endometriosis. Naringenin is a phytoestrogen with estrogenic and anti-estrogenic activities and mainly extracted from citrus fruits (Gao et al., 2006) . Naringenin is a promising anti-proliferative, anti-inflammatory and antioxidant phytoestrogen that inhibits proliferation of human epidermoid carcinoma cells through ROS production and cell cycle arrest (Ahamad et al., 2014) . Also, it inhibits AKT cell signaling to exert antiproliferative effects and induce apoptosis in gastric cancer cells (Bao et al., 2016) . Moreover, naringenin induces cell death through regulating mitochondrial membrane potential and decreasing phosphorylation of B-cell lymphoma 2 (Bcl-2) and increasing a pro-apoptotic molecule, Bax (Kanno et al., 2006; Park et al., 2008; Sabarinathan et al., 2010) . Furthermore, naringenin induces production of intracellular ROS in prostate cancer causing apoptosis (Lim et al., 2016) . However, most studies of naringenin-induced cell death have involved tumor cells. Thus, in the present study, we investigated the effects of naringenin on apoptosis of endometriosis cell lines VK2/E6E7 and End1/E6E7. Results of this study indicated that the naringenin promoted apoptosis of endometriosis cells by reducing cell proliferation and inducing DNA fragmentation. Naringenin increased mitochondrial-mediated apoptosis by inducing depolarization of MMP and the abundance of the proapoptitic protein Bax in VK2/E6E7 and End1/E6E7 cells. These results support those of previous studies with natural compound, including resveratrol and epigallocatechin gallate, that increase TUNEL-positive endometrial epithelial cells in patients with endometriosis (Ricci et al., 2013) .
Etiopathogenesis of endometriosis is related to chronic inflammation and ROS are known as proinflammatory regulators of cell proliferation (Ngo et al., 2009) . Excessive production of ROS results in cellular damage and abnormal function through modulation of gene expression and protein function in endometriosis. For instance, the increase in ROS levels in the peritoneal fluid influence idiopathic infertility in patients with endometriosis (Bedaiwy et al., 2002) . In addition, high levels of ROS mediate the DNA fragmentation in endometriosis by regulating expression of NF-κB that stimulates several genes encoding proinflammatory cytokines, growth and angiogenic factors, adhesion molecules and cyclooxygenases (Kaponis et al., 2012) . Also, an increase of ROS production is closely related to lipid peroxidation defined as the oxidative deterioration of polyunsaturated fatty acids. Specifically, in patients with endometriosis, lipid peroxidation commonly increases in response to treatment of patients with gonadotropins (Campos Petean et al., 2008) . Results of the present study indicate that naringenin increases intracellular ROS production, lipid peroxidation and DNA fragmentation leading to apoptosis of human endometriosis cells.
The accumulation of ROS in cells results in unfolded proteins responses inducing endoplasmic reticulum (ER)-stress. When ER stress induces activation of IRE1, protein kinase RNA-like ER kinase (PERK) and activating transcription factor-6 (ATF6), apoptosis is enhanced by activation of JNK and P38 MAPK cell signaling (Trondl et al., 2014) . Also, the phosphorylation of eIF2α, a downstream signaling molecule of PERK, occurs in response to ROS generation, increasing GADD153 protein which inhibits phosphorylation of Bcl-2 (Zeeshan et al., 2016) . Moreover, naringenin induces ER chaperone protein GRP78 which inhibits aggregation of polyglutamine-based diseases and this supports the use of naringenin as a potential therapeutic Figure 9 Hypothetical model for illustration of the mechanism whereby naringenin inhibits proliferation of endometriosis cells (VK2/E6E7 and End1/E6E7). Naringenin-induced cell death of human endometriosis cells involves loss of MMP, increases in production of ROS and lipid peroxidation in both endometriosis cell lines. In addition, naringenin increases phosphorylation mainly of P38 and ERK1/2 MAPK cell signaling proteins and inhibition of phosphorylation of AKT, P70S6K, S6 and P90RSK proteins in VK2/E6E7 and End1/E6E7 cells. Moreover, naringenin increases ER stress according to activation of eIF2α, IRE1α, GADD153 and GRP78 proteins in VK2/E6E7 and End1/E6E7 cell lines. Taken together, naringenin potentially suppresses progression and development of human endometriosis.
drug (Yamagishi et al., 2012) . In this study, the phosphorylation of eIF2α and IRE1α, GADD153 and GRP78, the primary ER stress chaperone proteins, increased in response to naringenin in human endometriosis cells. IRE1α activation is closely linked to cell death through activation of MAPK and downstream pro-apoptotic proteins splicing X-box binding protein 1 (XBP1) mRNA (Han et al., 2009) . We compared the phosphorylation of signal transduction molecules in naringenin treated VK2/E6E7 and End1/E6E7 endometriosis cell lines and found that phosphorylation of P38 and JNK increased in VK2/E6E7 cells, but only P38 increased in End1/E6E7 cells. In addition, naringenin inactivated PI3K/AKT signal transduction in both endometriosis cell lines. Moreover, inhibition of PI3K and MAPK with naringenin suppressed proliferation of human endometriosis cell lines as compared to naringenin or pharmacological inhibitor alone. Thus, naringenin increases apoptosis of human endometriosis cells through induction of ER stress, activation of MAPK signaling and inactivation of PI3K pathway.
Endometriosis has unclear pathogenetic history and there is no effective and fundamental treatment standard without surgery. Even though therapeutic approaches for endometriosis have changed from surgery to pharmacological drugs, more clinical studies aimed at reducing side effects are necessary (Practice Committee of the American Society for Reproductive, 2012; Johnson et al., 2013) . Results of the present study indicate that naringenin induces apoptosis by reduction of cell proliferation, depolarization of MMP and generation of ROS in VK2/E6E7 and End1/E6E7 cells. Moreover, it activates P38 MAPK and JNK MAPK, but inactivates PI3K/AKT signal transduction leading to death of endometriosis cells. These results suggest that naringenin may decrease progression and development of endometriosis and is a potential therapeutic agent. However, clinical trials using animal models of endometriosis are required before application of naringenin for treatment of endometriosis patients.
